Clinical Trial

A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 11, 2023 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To explore whether the adjuvant therapy of metronomic capecitabine could improve the disease-free survival of locoregionally advanced hypopharyngeal carcinoma (stage IV：T4N0-1M0，anyTN2-3M0).
Trial Details
NCT Number NCT05940441
Lead Sponsor Eye & ENT Hospital of Fudan University
Conditions to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma
Enrollment 74 participants
Start Date 2023-07-01
Primary Completion 2025-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2023-07-11